CARLOS ALBERTO IZAGUIRRE ROJAS

Dr. CARLOS ALBERTO IZAGUIRRE ROJAS

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2025 in Clinics and Practice
Verified
Journal Article
Open access
PDF file
NSNidha Shapoo
Nidha Shapoo
ARAbdul Rehman
Abdul Rehman
CRCARLOS ALBERTO IZAGUIRRE ROJAS
CARLOS ALBERTO IZAGUIRRE ROJAS
VGVladimir Gotlieb
Vladimir Gotlieb
NBNoella Boma
Noella Boma
Cancer pain remains a significant challenge in oncology, profoundly affecting patients’ quality of life, function, and prognosis. Historically under-recognized and managed with a uniform, opioid-centric approach, cancer pain was often inadequately treated. Advances in pain assessment, multimodal analgesia, and supportive care have improved outcomes, yet traditional algorithms frequently fail to address the complex, heterogeneous nature of cancer pain. Contemporary management is shifting toward precision and personalized medicine, integrating genetic, molecular, and biomarker data with individual patient characteristics to inform treatment decisions. To address this complexity, we propose a five-domain framework encompassing biological, pharmacologic, psychological, sociocultural, and functional domains. This multidimensional approach enables clinicians to tailor pain management strategies to each patient’s unique profile, aiming for equitable and individualized care. However, challenges remain, including tumor and patient heterogeneity, limited biomarker validation, data integration, disparities in access, and the need for multidisciplinary coordination. This review traces the evolution of cancer pain management, highlights the promise of precision and personalized strategies, and presents a comprehensive framework for optimizing pain control in oncology.

20 October 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
NSNidha Shapoo
Nidha Shapoo
CRCARLOS ALBERTO IZAGUIRRE ROJAS
CARLOS ALBERTO IZAGUIRRE ROJAS
ARAbdul Rehman
Abdul Rehman
JMJoseph Mattana
Joseph Mattana
VGVladimir Gotlieb
Vladimir Gotlieb
Background: Metastatic prostate cancer with BRCA2 mutation is associated with aggressive clinical behavior and poor outcomes with standard systemic therapy. While the BRCA2 mutation predicts response to PARP inhibitors and platinum agents, its association with paraneoplastic syndromes is not well described.Case Presentation: We report a 72-year-old male who presented with altered sensorium with severe hyponatremia who was diagnosed with syndrome of inappropriate antidiuretic hormone secretion (SIADH) in the context of newly diagnosed metastatic prostate adenocarcinoma. He was treated with free water restriction, hypertonic saline, and triplet systemic therapy (docetaxel, androgen deprivation, and darolutamide) and discharged in stable condition. After one year of disease remission, he developed generalized weakness, hematuria, thrombocytopenia, hemolytic anemia, and renal impairment. Peripheral smear demonstrated schistocytes, consistent with thrombotic microangiopathy (TMA). Bone marrow biopsy confirmed metastatic adenocarcinoma with a BRCA2 frameshift mutation (p. Trp1692MetfsTer3). ADAMTS13 activity was normal, excluding thrombotic thrombocytopenic purpura. He received five cycles of carboplatin/docetaxel chemotherapy along with blood and platelet support, with clinical and hematologic recovery, and was discharged on Olaparib, abiraterone, and leuprolide. Despite initial improvement, he succumbed to the disease within two months. Discussion: This case illustrates the aggressive biology of BRCA2-mutated prostate cancer, characterized by rapid progression and limited durability of standard therapies. While SIADH and TMA have been individually reported in prostate cancer, their sequential occurrence in a BRCA2-mutated setting is unique. The case highlights the vigilance for atypical paraneoplastic manifestations, the need for early genomic testing, and the exploration of novel therapeutic strategies in BRCA2-driven disease.Conclusion: We present the first reported case of BRCA2-mutated metastatic prostate cancer complicated by the sequential development of SIADH and TMA, underscoring the aggressive clinical trajectory and poor prognosis associated with this molecular subtype.

26 March 2022 in Más Vita
Verified
Journal Article
Closed access
PDF file
ADArmida Concepción Rojas Dávila
Armida Concepción Rojas Dávila
DLDominga Gladys Zuñiga Lopez
Dominga Gladys Zuñiga Lopez
SVSoledad Victoria Casallo Véliz
Soledad Victoria Casallo Véliz
VZVirginia Eudocia Ortega Zenteno
Virginia Eudocia Ortega Zenteno
CRCARLOS ALBERTO IZAGUIRRE ROJAS
CARLOS ALBERTO IZAGUIRRE ROJAS
Introducción: Nuestro país presenta un gran potencial de plantas medicinales en todo su territorio, por ser megadiverso, con muchas regiones agroecologicas y formaciones vegetales, pese a ello es incipiente la atención al desarrollo de las cadenas de valor del potencial de plantas medicinales, constituyendo un desafío el registro adecuado, con calidad y seguridad porque previenen y solucionan dificultades de salud por sus principios activos. Argyrochosma nivea (Poir.) Windham, “cuti cuti” conocido también como Notholaena nivea. Objetivos: Determinar los grupos metabólicos del extracto alcohólico al 20% de Argyrochosma nivea (Poir.) Windham, administrado a pacientes de diabetes del programa de medicina complementaria, EsSALUD Huancayo. Materiales y métodos: Estudios descriptivo, comparativo. La recolección de información relevante de aspectos botánicos, etnobotánicos, etnofarmacológicos y fitoquímicos sobre Argyrochosma nivea se realizó mediante la búsqueda en las bases de datos Scopus, ScienceDirect, PubMed y la biblioteca virtual del CONCYTEC (servicio de esa institución que reúne revistas de SciELO-Perú y la producción científica y tecnológica del Perú); además, se utilizó el buscador Google-Académico con el fin de agotar la búsqueda. Los términos de búsqueda fueron “Argyrochosma nivea”, “Notholaena nivea” o “cuti cuti”. Resultados: La Tintura de Argyrochosma nivea al 20% preparado con alcohol etílico al 50% en el analisis fitoquimico realizado se encontro compuestos de Flavanoides totales 0.111 mg de Catequina/ml, Flavonoides totales 0.133 mg de Quercitina /ml, Polifenoles totales 5.189 mg de ácido gálico/ml, Capacidad Antioxidante* 424.701 µ mol trolox/ml, Rutina 0.00579 mg de Rutina/ml, Quercitina 0.105mg/ml y Cumarinas 0.170 mg /ml. Ausencia de antocianinas totales, estos valores aportan la capacidad antioxidante de “cuti cuti”, y el contenido de flavonoides (quercetina), permite la prevalencia en el tratamiento de la diabetes. Conclusión: El Estudio fitoquimico de Argyrochosma nivea (Poir.) Windham (Cuti cuti) mediante el análisis por espectrofotometría y análisis por HPLC verifico la existencia de 7 compuestos Flavanoides totales 0.111 mg de Catequina/ml, Flavonoides totales 0.133 mg de Quercitina /ml, Polifenoles totales 5.189 mg de ácido gálico/ml, Capacidad Antioxidante* 424.701 µ mol trolox/ml, Rutina 0.00579 mg de Rutina/ml, Quercitina 0.105mg de Qu ercitina/ml y Cumarinas 0.170 mg de Cumarina/ml. SUMMARY Introduction: Our country has a great potential for medicinal plants throughout its territory, as it is megadiverse, with many agroecological regions and plant formations, despite this, attention to the development of value chains for the potential of medicinal plants is incipient, constituting a I challenge the proper registration, with quality and safety because they prevent and solve health difficulties due to their active ingredients. Argyrochosma nivea (Poir.) Windham, "cuti cuti" also known as Notholaena nivea. Objectives: To determine the metabolic groups of the 20% alcoholic extract of Argyrochosma nivea (Poir.) Windham, administered to diabetes patients of the complementary medicine program, EsSALUD Huancayo. Methods: Descriptive, comparative studies. The collection of relevant information on botanical, ethnobotanical, ethnopharmacological and phytochemical aspects of Argyrochosma nivea was carried out by searching the Scopus, ScienceDirect, PubMed databases and the virtual library of CONCYTEC (a service of that institution that brings together SciELO-Peru journals). and the scientific and technological production of Peru); In addition, the Google Academic search engine was used in order to exhaust the search. The search terms were “Argyrochosma nivea”, “Notholaena nivea” or “cuti cuti”. Results: The Argyrochosma nivea tincture at 20% prepared with 50% ethyl alcohol in the phytochemical analysis carried out found compounds of total Flavanoids 0.111 mg of Catechin / ml, total Flavonoids 0.133 mg of Quercetin / ml, total Polyphenols 5.189 mg of acid gallic/ml, Antioxidant Capacity* 424.701 µmol trolox/ml, Rutin 0.00579 mg Rutin/ml, Quercetin 0.105mg/ml and Coumarins 0.170 mg/ml. Absence of total anthocyanins, these values provide the antioxidant capacity of "cuti cuti", and the content of flavonoids (quercetin), allows prevalence in the treatment of diabetes. Conclusion: The phytochemical study of Argyrochosma nivea (Poir.) Windham (Cuti cuti) through spectrophotometric analysis and HPLC analysis verified the existence of 7 total Flavanoid compounds 0.111 mg of Catechin/ml, total Flavonoids 0.133 mg of Quercetin /ml, Total polyphenols 5.189 mg of gallic acid/ml, Antioxidant Capacity* 424.701 µ mol trolox/ml, Rutin 0.00579 mg of Rutin/ml, Quercetin 0.105mg of Quercetin/ml and Coumarins 0.170 mg of Coumarin/ml.

1 July 2022 in Más Vita
Verified
Journal Article
Open access
PDF file
ADArmida Concepción Rojas Dávila
Armida Concepción Rojas Dávila
DLDominga Gladys Zúñiga López
Dominga Gladys Zúñiga López
SVSoledad Victoria Casallo Véliz
Soledad Victoria Casallo Véliz
VZVirginia Eudocia Ortega Zenteno
Virginia Eudocia Ortega Zenteno
CRCARLOS ALBERTO IZAGUIRRE ROJAS
CARLOS ALBERTO IZAGUIRRE ROJAS
Introducción: La diabetes tipo 2 es un trastorno metabólico progresivo complejo, que representa una amenaza significativa para la salud humana y representa más del 91% de todos los casos de diabetes. Objetivo: evaluar el efecto de la adición de tintura de Notholaena nivea al tratamiento con metformina en pacientes con tolerancia alterada a la glucosa (IGT) y diabetes de tipo 2 (DMT2). Materiales y Método: Ensayo clínico unicentral, aleatorizado, simple ciego, controlado con placebo. Todos los participantes con diagnóstico de IGT y DMT2 que tomaban metformina fueron asignados aleatoriamente a recibir kits con tintura de Notholaena nivea autentica (40 pacientes) o placebo (58 pacientes), fijando 6 gotas diarias, 30 minutos antes del desayuno y almuerzo durante 26 semanas, se hicieron 3 controles (0, 13 y 26 semanas) midiendo glucosa plasmática en ayunas (FPG), nivel de hemoglobina glucosilada (HbA1C) y perfil lipídico. Resultados: del grupo de tratamiento (tintura de Notholaena nivea más metformina) fueron significativamente eficientes a las 13 semanas de iniciado el ensayo, manteniendo la directriz de reducción de glucosa plasmática (FPG), al iniciar el estudio el grupo control y tratamiento obtuvieron niveles de FPG similares con valores de .57±1.7 y 7.84±1.9 mmol/l respectivamente (p>0.05), a las 13 semanas se redujo a 7.21±1.mmol/l para el grupo control y 6.49±2.33 mmol/l para el grupo tratamiento (p<0.01), mientras que a la semana 26 el grupo control reporto 7.09±1.41 mmol/l en tanto el grupo tratamiento obtuvo 5.98±0.71 mmol/l (p0.05). Conclusiones: el tratamiento combinado de metformina más tintura de Notholaena nivea reduce acelerada y eficazmente las concentraciones de FPG en sangre de pacientes con IGT o DMT2, pero es ineficaz en el tratamiento del perfil lipídico. SUMMARY Introduction: Type 2 diabetes is a complex progressive metabolic disorder, which represents a significant threat to human health and accounts for more than 91% of all diabetes cases. Objective: to evaluate the effect of adding Notholaena nivea tincture to metformin treatment in patients with impaired glucose tolerance (IGT) and type 2 diabetes (DMT2). Materials and Method: Unicentral, randomized, single-blind, placebo- controlled clinical trial. All participants diagnosed with IGT and T2DM who were taking metformin were randomly assigned to receive authentic Notholaena nivea tincture kits (40 patients) or placebo (58 patients), setting 6 drops daily, 30 minutes before breakfast and lunch for 26 weeks. , 3 controls were made (0, 13 and 26 weeks) measuring fasting plasma glucose (FPG), glycosylated hemoglobin level (HbA1C) and lipid profile. Results: the treatment group (Notholaena nivea tincture plus metformin) were significantly efficient at 13 weeks from the start of the trial, maintaining the plasma glucose reduction guideline (FPG), at the start of the study the control and treatment groups obtained levels of Similar FPG with values of .57±1.7 and 7.84±1.9 mmol/l respectively (p>0.05), at 13 weeks it was reduced to 7.21±1.mmol/l for the control group and 6.49±2.33 mmol/l for the treatment group (p<0.01), while at week 26 the control group reported 7.09±1.41 mmol/l while the treatment group obtained 5.98±0.71 mmol/l (p0.05). Conclusions: the combined treatment of metformin plus Notholaena nivea tincture rapidly and effectively reduces FPG concentrations in the blood of patients with IGT or DMT2, but it is ineffective in the treatment of the lipid profile.Keywords: Type 2 diabetes, Notholaena nivea, FPG, Metformin, lipids